Concert Pharma initiates CKD drug Phase 1 clinical study
CTP-499, invented using Concert’s DCE Platform (deuterated chemical entity platform), is a potential first-in-class treatment for chronic kidney disease. It is a deuterium containing new chemical entity which
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.